In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events.

Topics include:

• Currently approved ICIs
• Role of biomarker and PD-L1 testing in advanced NSCLC
• Strategies to individualize ICI treatment for patients with advanced NSCLC
• Strategies for identifying and managing immune-related adverse events in patients treated with ICI

Presenter:
Sandip P. Patel, MD
Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California – San Diego
La Jolla, California 

Link to full program:
https://bit.ly/39vuCHC